The biological classification of mental disorders (BeCOME) study: a protocol for an observational deep-phenotyping study for the identification of biological subtypes

Tanja Brückl(Max Planck Institute of Psychiatry), Victor I. Spoormaker(Max Planck Institute of Psychiatry), Philipp G. Sämann(Max Planck Institute of Psychiatry), Anna‐Katharine Brem(Beth Israel Deaconess Medical Center), Lara Henco(Max Planck Institute of Psychiatry), Darina Czamara(Max Planck Institute of Psychiatry), Immanuel Elbau(Max Planck Institute of Psychiatry), Norma C. Grandi(Max Planck Institute of Psychiatry), Lee Jollans(Max Planck Institute of Psychiatry), Anne Kühnel(Max Planck Institute of Psychiatry), Laura Leuchs(Max Planck Institute of Psychiatry), Dorothee Pöhlchen(Max Planck Institute of Psychiatry), Maximilian Schneider(Max Planck Institute of Psychiatry), Alina Tontsch(Max Planck Institute of Psychiatry), Martin E. Keck(Max Planck Institute of Psychiatry), Leonhard Schilbach(Max Planck Institute of Psychiatry), Michael Czisch(Max Planck Institute of Psychiatry), Susanne Lucae(Max Planck Institute of Psychiatry), Angelika Erhardt(Max Planck Institute of Psychiatry), Elisabeth B. Binder(Emory University)
BMC Psychiatry
May 11, 2020
Cited by 63Open Access
Full Text

Abstract

BACKGROUND: A major research finding in the field of Biological Psychiatry is that symptom-based categories of mental disorders map poorly onto dysfunctions in brain circuits or neurobiological pathways. Many of the identified (neuro) biological dysfunctions are "transdiagnostic", meaning that they do not reflect diagnostic boundaries but are shared by different ICD/DSM diagnoses. The compromised biological validity of the current classification system for mental disorders impedes rather than supports the development of treatments that not only target symptoms but also the underlying pathophysiological mechanisms. The Biological Classification of Mental Disorders (BeCOME) study aims to identify biology-based classes of mental disorders that improve the translation of novel biomedical findings into tailored clinical applications. METHODS: BeCOME intends to include at least 1000 individuals with a broad spectrum of affective, anxiety and stress-related mental disorders as well as 500 individuals unaffected by mental disorders. After a screening visit, all participants undergo in-depth phenotyping procedures and omics assessments on two consecutive days. Several validated paradigms (e.g., fear conditioning, reward anticipation, imaging stress test, social reward learning task) are applied to stimulate a response in a basic system of human functioning (e.g., acute threat response, reward processing, stress response or social reward learning) that plays a key role in the development of affective, anxiety and stress-related mental disorders. The response to this stimulation is then read out across multiple levels. Assessments comprise genetic, molecular, cellular, physiological, neuroimaging, neurocognitive, psychophysiological and psychometric measurements. The multilevel information collected in BeCOME will be used to identify data-driven biologically-informed categories of mental disorders using cluster analytical techniques. DISCUSSION: The novelty of BeCOME lies in the dynamic in-depth phenotyping and omics characterization of individuals with mental disorders from the depression and anxiety spectrum of varying severity. We believe that such biology-based subclasses of mental disorders will serve as better treatment targets than purely symptom-based disease entities, and help in tailoring the right treatment to the individual patient suffering from a mental disorder. BeCOME has the potential to contribute to a novel taxonomy of mental disorders that integrates the underlying pathomechanisms into diagnoses. TRIAL REGISTRATION: Retrospectively registered on June 12, 2019 on ClinicalTrials.gov (TRN: NCT03984084).


Related Papers

No related papers found

Powered by citation graph analysis